drugset / Trial / NCT04982146
Intratumoral Bromelain + Acetylcysteine in Relapsed and Unresectable Pseudomyxoma Peritonei
NaSingle-groupOpen-labelTreatment
Summary
This trial pursues studying a compassionate treatment option for patients with inoperable pseudomyxoma peritonei through percutaneous administration of bromelain + N-acetylcysteine (NAC) in order to decrease tumoral volume. Secondary endpoints are the decrease of ascites, compressive symptoms and pain through the dilution of mucins, which would better intestinal blockage.
Timeline
- Start
- 2021-09-13
- Primary completion
- 2022-05-16
- Completion
- 2023-05-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bromelain | Protein / enzyme biologic | 0.5 mg/ml | Other |
| Subject | N-acetylcysteine | Small molecule | 20 mg/ml | Other |